162.20
+3.17
+(1.99%)
At close: January 10 at 5:54:30 PM GMT-3
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 18 | 3 | 29 | 29 |
| Avg. Estimate | 13.96B | 12.93B | 45.56B | 58.5B |
| Low Estimate | 13.17B | 12.13B | 44.68B | 53.84B |
| High Estimate | 14.34B | 13.43B | 46.11B | 66.81B |
| Year Ago Sales | 9.35B | 8.77B | 34.12B | 45.56B |
| Sales Growth (year/est) | 49.22% | 47.49% | 33.51% | 28.41% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| LILY34.SA | -- | -- | -- | -- |
| S&P 500 | 8.59% | 11.42% | 13.98% | 13.43% |
Related Tickers
N1VS34.SA Novartis AG
60.88
+1.01%
BMY.BA Bristol-Myers Squibb Company
22,225.00
-5.43%
BRM.HM Bristol-Myers Squibb Co
54.77
+0.31%
N1VO34.SA Novo Nordisk A/S
65.63
+0.67%
BRM.F Bristol-Myers Squibb Company
54.23
-1.20%
NOVO-B.CO Novo Nordisk A/S
632.30
+0.37%
AZN AstraZeneca PLC
67.01
+0.65%
NVO Novo Nordisk A/S
86.26
+0.72%
PFE Pfizer Inc.
26.72
-0.52%
JNJ Johnson & Johnson
142.06
-0.15%